Lakefront Biotherapeutics (GLPGF) Cash from Operations Growth (1y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Cash from Operations Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | -28.96% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 42.76% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 178.99% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -138.56% |
| Dec 31, 2025 | 12.92% |
| Mar 31, 2025 | 69.47% |
| Dec 31, 2024 | 85.48% |
| Mar 31, 2024 | -30.62% |
| Dec 31, 2023 | 14.47% |
| Mar 31, 2023 | -46.41% |
| Dec 31, 2022 | 11.40% |
| Mar 31, 2022 | 52.43% |
| Dec 31, 2021 | -13.12% |
| Jun 30, 2021 | 36.46% |
| Mar 31, 2021 | -92.29% |
| Dec 31, 2020 | -283.14% |
| Jun 30, 2020 | -97.27% |
| Mar 31, 2020 | 6.70% |
| Dec 31, 2019 | 18.22% |
| Sep 30, 2019 | 91,312.06% |
| Jun 30, 2019 | -28.11% |
| Mar 31, 2019 | -66.65% |
| Dec 31, 2018 | 6.07% |